All News
Sarilumab in pts with relapsing PMR - Phase 3 trial
Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%)
Less flare occurrences
Sarilumab noted to have higher incidences of neutropenia, arthralgia
@RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3
Robert B Chao, MD doctorRBC ( View Tweet)
Biosimilars and COVID vaccines have made nocebo more pertinent than ever.
How do we combat it?
First line is good communication, and the foot soldiers are the right phrases.
Language matters. #EULAR2022 @RheumNow https://t.co/U0Chv9ia1G
David Liew drdavidliew ( View Tweet)
Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change.
In the 2022 version:
JAKi now separate sentence following bDMARDs, with proviso to mention risk.
Sometimes guidelines have to tell us what we’ve all inevitably been expecting
#EULAR2022 @RheumNow https://t.co/RPbPNi3vcW
David Liew drdavidliew ( View Tweet)
#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Does treating spondyloarthritis early matter?
Systematic review showed in nr-axSpA tx with biologics may lead to better outcomes compared to established axSpA
axSpA - no difference in response between early vs. established disease
@RheumNow #EULAR2022 ABST#POS0302
Robert B Chao, MD doctorRBC ( View Tweet)
Sarilumab in PMR
SAPHYR Phase 3 RCT
Underpowered (<50% target recruitment)
-% remission sustained from wk12 to wk 52
28% vs 10% PBO
-Risk of flare reduced HR 0.56
-Improvement of several PROs
No new safety signal
LB0006 @RheumNow #EULAR2022 https://t.co/n7WdQxQaHo
Aurelie Najm AurelieRheumo ( View Tweet)
SAPHYR phase 3 RDBPCT study: #sarilumab vs PCB for relapsing #PMR on pred 7.5+ mg/d. Study met endpoints (whether of or not CRP was included). Time to first flare was longer w/SARI, less steroid use, and also better PROs. AE: #EULAR2022 LB0006 @rheumnow 1/2 https://t.co/lIspLKlveb
TheDaoIndex KDAO2011 ( View Tweet)
Redondo-Rodriguez et al. Abatacept in RA-ILD. Prospective study 38 patients. 73.6% improved/stablised with abatacept at median 17 month follow-up @RheumNow #EULAR2022 POS0654 https://t.co/D2du0hAXIy
Richard Conway RichardPAConway ( View Tweet)
#POS1207 #EULAR2022 In N=98 RA patients with poor antibody response to rituximab after two doses, 19% responded after 3rd dose. Associated with longer Time of vaccine from last RTX & interestingly ultra dose 200mg used in the Netherlands @RheumNow https://t.co/TTXXtOU6vp
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
BRIDGE-PMR (rituximab in PMR) routine care extension to 52w
(in #PMRGCAJC one big qu asked was ?sustained benefit)
sustained benefit (RR 2.5 GC-free remission)
steroid-sparing (PNL 1.6g v 2.3g)
& ritux ?cheap enough now
but COVID calculus difficult
POS0269 #EULAR2022 @RheumNow https://t.co/Ln2ArclKO8 https://t.co/OtCwdjIPeL
David Liew drdavidliew ( View Tweet)
CorEvitas PsA Registry (1000+ pts)
Analysis of biologics prescription according to disease domains
No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL
Overall first line TNFi 40% > IL-17i 14%
POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug
Aurelie Najm AurelieRheumo ( View Tweet)
EULAR 2022 – Day 3 Report
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Read Article
Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ
Richard Conway RichardPAConway ( View Tweet)
Please see my short video on Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients #EULAR2022 @RheumNow https://t.co/bqzdWIzoOg
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
den Broeder et al. Follow-up to REDO study. Ultra-low dose RTX non-inferior for DAS28CRP. 1000mg 2.2 (2.0-2.4), 500mg 2.2 (2.1-2.4), 200mg 2.3 (2.2-2.5) (all given 6-monthly). Small effect by received dose though (0.15 per 1000mg) @RheumNow #EULAR2022 POS0652 https://t.co/hfSw9ndQpk
Richard Conway RichardPAConway ( View Tweet)
Campaniello et al. Ultra-low dose RTX (500/1000mg once a year) vs low dose RTX (500/1000mg 6-monthly) for maintenance in AAV. Comparable relapse free survival 22.7% vs 21.2%, lower severe infection 10.5% vs 26.8% @RheumNow #EULAR2022 POS0837 https://t.co/uBgEmhLUzv
Richard Conway RichardPAConway ( View Tweet)
Frisell et al. Safety b/tsDMARDs from 10 years ARTIS. There is a mass of interesting data here, look at that figure! Higher rates of discontinuation due to AEs for tofa, bari, sari, rituximab. May be explained by chanelling and residual confounding @RheumNow #EULAR2022 POS0637 https://t.co/KrspU6c9Cs
Richard Conway RichardPAConway ( View Tweet)
Pharmacodynamic effect of sequential #belimumab and #rituximab therapy in patients with systemic #lupus: BLISS-BELIEVE study
#EULAR2022
>CR https://t.co/AgBBuqYatW
ARD & RMD Open ARD_BMJ ( View Tweet)
Alsing et al. Dutch study. Persistent excess stroke risk in RA in biologic era. @RheumNow #EULAR2022 OP0277 https://t.co/oLmsrniKw6 https://t.co/2zDkuUzq0S
Links:
Richard Conway RichardPAConway ( View Tweet)
A new finding - antimalarials improve safety w bDMARDs & #JAKi and reduce CV events and improve drug survival #Bestinclass. POS0242 @RheumNow @eular_org #EULAR2022 Neat. Safe, inexpensive and monitor eyes 👀 https://t.co/Ea4VA9vqwe
Janet Pope Janetbirdope ( View Tweet)